Gilead voluntarily recalls one lot of injected AIDS-related infection drug

Vials of Vistide containing particulate matter found

FOSTER CITY, Calif. — Drug maker Gilead Sciences has recalled a single lot of an injected drug used to treat an opportunistic infection in AIDS patients due to the presence of foreign matter in some vials, the company said.

Gilead announced the voluntary recall of lot B120217A of Vistide (cidofovir), an injected drug used to treat cytomegalovirus retinitis in patients with AIDS, due to particulate matter.

The company said that it had not received any complaints related to the problem, but that patients risked experiencing serious complications if injected with the particles. The lot was distributed in the United States, Canada and Europe to retail pharmacies, hospitals and wholesalers.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.